Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Jean-Jacques Lafitte"'
Autor:
Thierry Berghmans, Arnaud Scherpereel, Anne-Pascale Meert, Vicente Giner, Jacques Lecomte, Jean-Jacques Lafitte, Nathalie Leclercq, Marianne Paesmans, Jean-Paul Sculier, for the European Lung Cancer Working Party (ELCWP)
Publikováno v:
Frontiers in Oncology, Vol 7 (2017)
IntroductionIn a literature meta-analysis, we showed survival benefits for regimens including cisplatin [hazard ratio (HR) 0.61; 95% confidence interval (CI), 0.57–0.66] and for those including etoposide (HR 0.65; 0.61–0.69). That benefit was mai
Externí odkaz:
https://doaj.org/article/def77f8f82b74a1db40ee3da9b8c1674
Autor:
Luigi Moretti, Anne-Pascale Meert, Nicolas Girard, Jean-Jacques Lafitte, Christiane Jungels, Valérie Durieux, Martine Roelandts, Thierry Berghmans, Stéphane Holbrechts, Sebahat Ocak
Publikováno v:
Lung cancer, Vol. 126, p. 25-31 (2018)
Thymic tumours are rare diseases that for most of the cases are cured with surgery and eventually adjuvant radiotherapy. However, about 30% of patients present with advanced stage or relapsing tumours, which require administration of chemotherapy. Wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff8b4447e4ba813e9f746a0510da31d4
https://hdl.handle.net/2078.1/208839
https://hdl.handle.net/2078.1/208839
Autor:
Arnaud Scherpereel, Thierry Berghmans, Jean-Paul Sculier, Marianne Paesmans, Jean-Jacques Lafitte, Anne-Pascale Meert, Nathalie Leclercq, Jacques Lecomte, V. Giner
Publikováno v:
11.1 Lung Cancer.
In a meta-analysis of the literature (Lung Cancer 30: 23-36; 2000), we showed survival benefits for regimens including cisplatin (Hazard ratio HR 0.61; 95 % CI, 0.57–0.66) and for those including etoposide (HR 0.65; 0.61–0.69).That benefit was ma
Autor:
Arnaud Scherpereel, Thierry Berghmans, Alexis B. Cortot, Céline Mascaux, Jean-Paul Sculier, Ingrid CsToth, Lieveke Ameye, Marianne Paesmans, Luc Willems, Anne-Pascale Meert, L Toussaint, Nathalie Leclercq, Tiffany Dernies, Jean-Jacques Lafitte
Publikováno v:
Lung Cancer. 82:340-345
Clinical variables, like stage and performance status (PS), have predictive and prognostic values in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy, not allowing adequate individual prediction. MicroRNA (miRNA) are non
Autor:
Anne-Pascale Meert, Olivier Van Cutsem, Vicente Giner, Martine Roelandts, Nathalie Leclercq, Yves Bonduelle, Arnaud Scherpereel, Thierry Berghmans, Benoit Colinet, Jean-Paul Sculier, Jean-Jacques Lafitte, Paul Van Houtte, Marianne Paesmans
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 117
Objectives To assess if induction radiochemotherapy followed by consolidation chemotherapy (arm A) will improve survival in comparison with the same chemotherapy given as induction followed by consolidation concurrent radiochemotherapy (arm B) in pat
Autor:
Jean-Paul Sculier, Anne-Pascale Meert, Oswald Van Cutsem, Nathalie Leclercq, Paul Van Houtte, Jean-Jacques Lafitte, Martine Roelandts, Arnaud Scherpereel, Thierry Berghmans, Benoit Colinet, Marianne Paesmans
Publikováno v:
11.1 Lung Cancer.
Rationale: Concomitant RT-CT demonstrated survival advantage for stage III NSCLC. A few phase II studies comparing induction to consolidation RT-CT cannot allow definitive conclusion. The ELCWP designed a phase III trial with survival as primary endp
Autor:
Jean-Jacques Lafitte, Lieveke Ameye, Ingrid CsToth, Nathalie Leclercq, Luc Willems, Jean-Paul Sculier, Tiffany Dernies, Stéphane Holbrechts, Marianne Paesmans, Christian Tulippe, Anne-Pascale Meert, Jacques Lecomte, Michel Richez, Céline Mascaux, Arnaud Scherpereel, Thierry Berghmans, Benoit Colinet, Alexis B. Cortot
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 4 (2015)
Frontiers in oncology, 4
Frontiers in Oncology, Vol 4 (2015)
Frontiers in oncology, 4
Aim: Cisplatin doublets are standard 1st line treatment for advanced non-small cell lung cancer (NSCLC), without accurate predictor for response and survival, but important toxicity. Our aims were to identify predictive (for response) and prognostic
Autor:
George Koumakis, Jacques Thiriaux, Jean-Paul Sculier, Thierry Berghmans, V. Giner, P. VanHoutte, Peggy Wackenier, P. Lothaire, Paul Mommen, Jean-Jacques Lafitte, Michel Richez, J.-L. Corhay, Anna Efremidis, J. Lecomte, Vincent Ninane
Publikováno v:
Lung Cancer. 45:339-348
The 1997 International staging system (ISS) classification separated stage III non-small cell lung cancer (NSCLC) into stages IIIA and IIIB. In a previous study including unresectable NSCLC initially treated with chemotherapy, we analysed survival ac
Autor:
Constantinos Alexopoulos, Vincent Ninane, M.C. Florin, Paul Mommen, Jacques Thiriaux, P Recloux, Anna Efremidis, J. Lecomte, Thierry Berghmans, Jean Klastersky, Marianne Paesmans, Jean-Jacques Lafitte, Jean-Paul Sculier
Publikováno v:
Annals of Oncology. 13:874-882
Objective To determine, in stage IV non-small-cell lung cancer (NSCLC), if the combination of gemcitabine—a new active drug—with ifosfamide (IG) or with the cisplatin-carboplatin association (CCG) will improve survival (primary end point) in comp
Autor:
Thierry, Berghmans, Jean-Jacques, Lafitte, Arnaud, Scherpereel, Marianne, Paesmans, Jacques, Lecomte, Vicente Giner, Marco, Anne-Pascale, Meert, Nathalie, Leclercq, Jean-Paul, Sculier
Publikováno v:
Anticancer research. 33(12)
While meta-analyses and clinical trials show improved survival in advanced NSCLC treated with platinum-containing chemotherapy, there are few data concerning front-line platinum-free ifosfamide-based regimens. We aimed to compare cisplatin-based chem